UNITED STATES PATENT AND TRADEMARK OFFICE

_____

BEFORE THE PATENT TRIAL AND APPEAL BOARD

_____

DR. REDDY'S LABORATORIES, S.A. AND
DR. REDDY'S LABORATORIES, INC.,
Petitioners,

v.

EYE THERAPIES, LLC,
Patent Owner.

_____

Case No.: IPR2024-00563

U.S. Patent No.: 11,596,600

_____

PETITIONERS' FIFTH UPDATED EXHIBIT LIST

Exhibit List

IPR	Description
1001	U.S. Patent No. 11,596,600 (filed Jan. 30, 2023) (issued Dec. 5, 2023) ('600 patent).
1002	U.S. Patent No. 8,293,742 (filed July 27, 2009) (issued Oct. 23, 2012) ('742 Patent).
1003	*Slayback Pharma LLC v. Eye Therapies, LLC*, No. IPR2022-00142, Paper 77 (P.T.A.B. May 15, 2023).
1004	U.S. Patent No. 6,294,553 (filed Feb. 14, 2001) (issued Sep. 25, 2001) (Gil).
1005	Not Used
1006	Norden, R., "Effect of Prophylactic Brimonidine or Bleeding Complications and Flap Adherence after Laser in Situ Keratomileusis," *Journal of Refractive Surgery*, vol. 18, no. 4, July/ Aug. 2002 at 468–471.
1007	U.S. Patent 6,242,442 (filed Dec. 7, 1999) (issued June 5, 2001) (Dean).
1008	"Alphagan® (brimonidine tartrate ophthalmic solution) 0.2%." *in* PHYSICIANS' DESK REFERENCE 487 (52th ed., 1998).
1009	53 Fed. Reg. 43, 7076-7093 (Mar. 4, 1988).
1010	File Wrapper, U.S. Application for 17/585.395 filed January 26, 2022, downloaded from Patent Center.
1011	Not Used
1012	Declaration of Reza Dana MD, MSc, MPH
1013	Declaration of Paul A. Laskar, Ph.D.
1014	Declaration of John Galanis MD, FACS

1015	Not Used
1016	U.S. Provisional Application 61/207,481 filed February 12, 2009, downloaded from PAIR ('481 Provisional).
1017	Not Used
1018	Not Used
1019	Not Used
1020	Griffith, R. K., "Adrenergics and Adrenergic- Blocking Agents." *Burger's Medicinal Chemistry and Drug Discovery*, edited by Donald J. Abraham, 6th ed., vol. 6, John Wiley & Sons, Inc., New York, NY, 2003, pp. 2–37.
1021	David, R. "Brimonidine (Alphagan®): A Clinical Profile Four Years after Launch." *European Journal of Ophthalmology*, vol. 11, no. 2_suppl, 2001, pp. S72–S77.
1022	Wikberg-Matsson, A., and Simonsen, U. "Potent α_{2A}-Adrenoceptor–Mediated Vasoconstriction by Brimonidine in Porcine Ciliary Arteries." *Investigative Ophthalmology & Visual Science*, vol. 42, no. 9, Aug. 2001, pp. 2049–2055.
1023	Robin, A. L., and Burnstein, Y, "Selectivity of Site of Action and Systemic Effects of Topical Alpha Agonists." *Current Opinion in Ophthalmology*, vol. 9, no. 2, 1998, pp. 30–33.
1024	Lachkar, Y, and Dhanjill, S., "Effect of Brimonidine Tartrate on Ocular Hemodynamic Measurements." *Archives of Ophthalmology*, vol. 116, no. 12, Dec. 1998, pp. 1591–1594.
1025	Exec. Order No. 14,036, 86 C.F.R. 36987 (July 9, 2021).
1026	Letter from Janet Woodcock, Acting Comm'r of Food and Drug Admin., to Andrew Hirshfeld, Director of the U.S. Pat. and Trademark Off. (Sept. 10, 2021), available at https://www.fda.gov/media/152086/download?attachment (last visited January 23, 2024).

1027	U.S. Courts, Statistics and Reports, Table C-5, U.S. District Courts–Civil Federal Judicial Caseload Statistics (March 31, 2023), https://www.uscourts.gov/statistics/table/c-5/federal-judicial-caseload-statistics/2023/03/31 (last visited Jan. 22, 2024).
1028	Murphy, P. J., et al. "How Red Is a White Eye? Clinical Grading of Normal Conjunctival Hyperaemia." *Eye*, vol. 21, no. 5, 2006, pp. 633–638.
1029	Derick, R. J., et al. "Brimonidine Tartrate: A One-month Dose Response Study" *Ophthalmology*, vol. 104, no. 1, Jan. 1997, pp. 131–136.
1030	United States, Center for Drug Evaluation and Research, and Joanne Holmes. NDA 20-613 Alphagan™ (Brimonidine Ophthalmic Solution) 0.2% Sterile, vol. 1, U.S. Food and Drug Administration, 1985, pp. 1–286.
1031	U.S. Patent No. 11,833,245 (filed Jan. 30, 2023) (issued Dec. 5, 2023) ("'245 patent").
1031	Deposition Transcript of Daniel Gil, dated December 31, 2023. C.A. No. 21-16766 ("Gil PI Depo Transcript")
1032	David, R., et al. "Brimonidine in the Prevention of Intraocular Pressure Elevation Following Argon Laser Trabeculoplasty," *Archives of Ophthalmology*, vol. 111, No. 10, Oct. 1993, pp. 1387–1390
1033	Declaration of Robert Frederickson III in Support of Notice of Intent to Designate Provisionally Recognized PTAB Attorney as Back-Up Counsel under 37 C.F.R. § 42.10(c)
1034	U.S. Patent No. 6,562,873 (filed July 10, 2001) (issued May 13, 2003)
1035	Burke, J., and Schwartz, M., "Preclinical Evaluation of Brimonidine." Survey of Ophthalmology, vol. 41, no. 1, Nov. 1996, pp. S9–S18
1036	Declaration of Elaine H. Blais in Support of Notice of Intent to Designate Provisionally Recognized PTAB Attorney as Back-Up Counsel under 37 C.F.R. § 42.10(c)
1037	Not Used

1038	Declaration of Timothy J. Beavers in Support of Notice of Intent to Designate Provisionally Recognized PTAB Attorney as Back-Up Counsel Under 37 C.F.R. § 42.10(c)
1039	*In re Lumify*, No. 3:21-cv-16766-RK-RLS, D.I. 17 (D.N.J. Mar. 10, 2022)
1040	U.S. Pharmacopeia 28-National Formulary 23, 2005
1041	Conrad, J.M., et al., "Influence of Tonicity and pH on Lacrimation and Ocular Drug Availability", *Journal of the Parenteral Drug Association*, vol. 32, no. 4, July-Aug. 1978, pp. 149-161.
1042	Gonnering, R., et al., "The pH Tolerance of Rabbit and Human Corneal Endothelium," *Investigative Ophthalmology & Visual Science*, vol. 18, no. 4, pp. 373-390, Apr. 1979
1043	Naphcon A, Alcon Laboratories, Inc.
1044	Deposition Transcript of Eric Donnenfeld, dated February 6, 2025 ("Donnenfeld IPR Depo Transcript")
1045	Deposition Transcript of Daniel Stamer, dated February 13, 2025 ("Stamer IPR Depo Transcript")
1046	Aieta, E.M. and Roberts, P.V., "The chemistry of oxo-chlorine compounds relevant to chlorine dioxide generation", *Water Chlorination: Chemistry, Environmental Impact and Health Effects*, vol. 1985, pp. 783–794
1047	Deposition Transcript of Robert Noecker, dated February 19, 2025 ("Noecker IPR Depo Transcript")
1048	Deposition Transcript of Robert Williams III, dated January 28, 2025 ("Williams IPR Depo Transcript")
1049	OPHTHALMIC SOLUTIONS OF REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 1380–1416 (19th ed., 1995)
1050	Langer S.Z. & Hicks, P.E., "Alpha-Adrenorecepter Subtypes in Blood Vessels: Physiology and Pharmacology," *Journal of Cardiovascular Pharmacology*, vol. 6, supp. 4, pp. S547-558, 1984
1051	Duka, et al., "Role of the Postsynaptic α_2-adrenergic Receptor Subtypes in Catecholamine-Induced Vasoconstriction," *General*

	Pharmacology: The Vascular System, vol. 34, no. 2, Feb. 2000, pp. 101-106
1052	Philipp M., Brede M., and Hein L., "Physiological significance of α_2-adrenergic receptor subtype diversity: one receptor is not enough", *American Journal of Physiology: Regulatory, Integrative and Comparative Physiology*, vol. 2, pp. R287–295, 2002
1053	Deposition Transcript of Robert Noecker, dated November 13, 2022. IPR2022-00142 ("Noecker '742 IPR Depo Transcript")
1054	Deposition Transcript of Eric Donnenfeld, dated January 21, 2024. C.A. No. 21-16766 ("Donnenfeld PI Depo Transcript")
1055	Spector S.L. & Raizman M.B., Conjunctivitis Medicamentosa, *Journal of Allergy and Clinical Immunology*, vol. 94, no. 1, pp. 134–136, July 1994
1056	C.N.S. Soparkar et al., *Acute and Chronic Conjunctivitis Due to Over-the-Counter Ophthalmic Decongestants*, 115 ARCHIVES OF OPHTHALMOLOGY 34 (1997)
1057	STEDMAN'S MEDICAL DICTIONARY (28th Ed 2006)
1058	ARVO Glossary, Eye and Vision Acronyms
1059	Carrington College, Decoding Your Prescriptions: Understanding Pharmacy Abbreviations, dated February 24, 2015
1060	Not Used
1061	OPHTHALMIC SOLUTIONS OF REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, Ch. 4, (20th ed., 2000)
1062	Aslanides I.M., et al., "Letter to the Editor," *Ophthalmology*, vol. 112, no. 12, Dec. 2005, pp. 2238.e8-2238.e9.
1063	Aslanides I.M., et al., "The Effect of Topical Apraclonidine on Subconjunctival Hemorrhage and Flap Adherence in LASIK Patients," *Journal of Refractive Surgery*, vol. 22, Jun. 2006, pp. 585-588
1064	Hong, S., et al., "Effect of Prophylactic Brimonidine Instillation on Bleeding During Strabismus Surgery in Adults," *American Journal of Ophthalmology*, vol. 144, no. 3, Sept. 2007 pp. 469-470

1065	NDC 4200220302, NDC 4200220335, Visine® Original Redness Relief Eye Drops (tetrahydrozoline) 0.05% (Visine Original Label)
1066	P. Agarwal, J. Craig, & I. D. Rupenthal, Review: Formulation Considerations for the Management of Dry Eye Disease, 13 PHARMACEUTICS 1 (2021).
1067	ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.5% Label (Dec. 2001), https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21262s6lbl.pdf (Alphagan Label 2001)
1068	ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%, (2006), https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021262s018lbl.pdf
1069	Z. Sklubalova, et al. *Systematic study of factors affecting eye drop size and dosing variability.* Pharmazie 60: 917–921 (2005)("Sklubalova 2005")
1070	Z. Sklubalova, et al., *Study of Eye Drops Dispensing and Dose Variability by Using Plastic Dropper Tips.* Drug Development and Industrial Pharmacy, 32:197–205, 2006. ("Sklubalova 2006")
1071	Naphcon A (naphazoline hydrochloride 0.025%, pheniramine maleate 0.3%), Alcon Laboratories (Naphcon A).
1072	Deposition Transcript of Robert Williams III, dated January 19, 2024 ("Williams PI Depo Testimony")
1073	D. N. Tzovolou, et al., *Capillary Electrophoretic Analysis of Brimonidine in Aqueous Humor of the Eye and Blood Sera and Relation of Levels with Intraocular Pressure*, 14 BIOMEDICAL CHROMATOGRAPHY 301 (2000).
1074	D. A. Lee, et. al, *The Effectiveness and Safety of Brimonidine as Mono-, Combination, or Replacement Therapy for Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Post Hoc Analysis of an Open-Label Community Trial*, 16 J. OCULAR PHARM. & THERAPEUTICS 3 (2000).

1075	Alphagan P (brimonidine tartrate ophthalmic solution) 0.1%, NDA No. 21770, Medical Review (2005).
1076–1111	Not Used
1112	T. Mundorf, et al., *A 3-Month Comparison of Efficacy and Safety of Brimonidine-Purite 0.15% and Brimonidine 0.2% in Patients with Glaucoma or Hypertension*, 19 J. OPHTHALMOLOGY & THERAPEUTICS 37 (2003).
1113-1128	Not Used
1129	Declaration of Robert J. Noecker, MD, MBA, Case No. IPR2022-00142 ("Noecker '742 Declaration")—Filed under seal
1130	Ö. Üretmen, et al., "Letter to the Editor," *Refractive Surgery*, vol. 19, 2013, p. 612.
1131	Desco, M.C., et al., "Effect of Prophylactic Brimonidine on Bleeding Complications After Cataract Surgery," *European Journal of Ophthalmology*, vol. 15 no. 2, 2005, pp. 228-232.
1132	Muñoz, G., et al., "Increased Risk for Flap Dislocation with Perioperative Brimonidine Use in Femtosecond Laser In Situ Keratomileusis," Journal of Cataract Refractive Surgery, vol. 35, 2009, pp. 1338–1342.
1133	Not Used
1134	K. Chuang, *Potential of Gene Editing and Induced Pluripotent Stem Cells (iPSCs) in Treatment of Retinal Diseases*, 90 Yale J. Bio. & Med. 635 (2017).
1135	K. Boyd and D. Turbert, *Eye Anatomy: Parts of the Eye and How We See,* AM. ACAD. OPHTHALMOLOGY, (Apr. 29, 2023), https://www.aao.org/eye-health/anatomy/parts-of-eye.
1136	*Scientists Discover Why Cornea is Transparent and Free of Blood Vessels, Allowing Vision*, SCHEPPENS EYE INSTITUTE, (July 17, 2006), https://www.eurekalert.org/news-releases/652982.

1137	K. Boyd, *What are Cataracts?*, AM. ACAD. OPHTHALMOLOGY, (Oct. 16, 2023), https://www.aao.org/eye-health/diseases/what-are-cataracts.
1138	H. Cronau, et al.*, Diagnosis and Management of Red Eye in Primary Care*, 81 AM. FAM. PHYSICIAN 2 (2010).
1139	S. L. Ackerman., *Lose-Dose Brimonidine for Relief of Ocular Redness: Integrated Analysis of Four Clinical Trials*, 102 CLINICAL & EXPERIMENTAL OPTOMETRY 131 (2019).
1140	E. McLaurin, et al., *Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial,* Optometry & Visual Science, vol. 95, no. 3, 2018, 264–271 (2018).
1141	G.L. Torkildsen, et al., *Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness*, 43 CURRENT EYE RESEARCH, 43 (2018).
1142	NDA020226, Naphcon A® (naphazoline hydrochloride) 0.025% and (pheniramine maleate) 0.3% ophthalmic solution
1143	NDA 019407, Visine® L.R. (oxymetazoline) 0.025%.
1144	Hosten, L., Snyder C., "Over-the-Counter Ocular Decongestants in the United States – Mechanisms of Action and Clinical Utility for Management of Ocular Redness," *Clinical Optometry*; vol. 12, 2020, pp. 95-105.
1145	Not Used
1146	Tal Raviv, *The Off-Label Use of Pharmaceuticals* (Nov. 23, 2002), https://talravivmd.com/the-off-label-use-of-pharmaceuticals/.
1147	Not Used
1147	Declaration of John C. Galanis, MD, FACS in Support of Petitioners' Reply ("Galanis Reply Report")
1148	H. Kaplan, *Anatomy and Function of the Eye*, *in* IMMUNE RESPONSE AND THE EYE, VOL. 92 (2d ed., 2007).

1149	M. Kuehn, et al., "Retinal Ganglion Cell Death in Glaucoma: Mechanisms and Neuroprotective Strategies," *Ophthalmology Clinic of North America*, vol. 18, Sept. 2005, pp. 383–395.
1150	R. Singh, et al., "Ocular redness – II: Progress in Development of Therapeutics for the Management of Conjunctival Hyperemia," *The Ocular Surface*, vol. 21, 2021, pp. 66–77.
1151	Wang, S., et al., "Therapeutic Efficacy of Topical Blockade of Substance P in Experimental Allergic Red Eye," *The Ocular Surface*, vol. 21, 2021, pp. 184–190.
1152	Utine, C.A., et al., "Radial Keratotomy for the Optical Rehabilitation of Mild to Moderate Keratoconus: More Than 5 Years' Experience," European Journal of Ophthalmology, vol. 16, no. 3, 2006, pp. 376–384.
1153	*Laser In Situ Keratomileusis (LASIK)*, NAT'L INST. HEALTH, NCBI BOOKSHELF, https://www.ncbi.nlm.nih.gov/books/NBK555970/ (last visited Jan. 5, 2024).
1154	J. Ruiz-Ederra, et al., *The Pig Eye As a Novel Model of Glaucoma*, 81 EXPERIMENTAL EYE RSCH. 561 (2005).
1155	Ventrella., D., et al., "The p-ERG Spatial Acuity in the Biomedical Pig Under Physiological Conditions," *Scientific Reports*, vol. 12, 2022, pp. 1–9.
1156	Crespo-Moral, M. et al., "Histological and Immunohistochemical Characterization of the Porcine Ocular Surface," *Plos One*, vol. 15, Jan. 13, 2020, pp. 1–17.
1157	R. Ruffolo, *Distribution and Function of Peripheral a-Adrenoceptors in the Cardiovascular System*, 22 PHARMACOLOGY BIOCHEM. & BEHAVIOR, 827 (1985).
1158	Z. P. Khan et al., *Alpha-2 and Imidazoline Receptor Agonists*, 54 ANAESTHESIA 146 (1999).
1159	S. Schonberg & T. Stokkermans, *Episcleritis*, *in* STATPEARLS (2023), https://www.ncbi.nlm.nih.gov/books/NBK534796/.

1160	M. B. Abelson & A. Vashishan, The Truth about Tachyphylaxis, Rev. Opthalmology (Mar. 16, 2006), https://www.reviewofophthalmology.com/article/the-truth-about-tachyphylaxis.
1161	K. Boyd, *What is Glaucoma? Symptoms, Causes, Diagnosis, Treatment,* AM. ACAD. OPHTHALMOLOGY, (Dec. 04, 2023), https://www.aao.org/eye-health/diseases/what-is-glaucoma (AAO Glaucoma).
1162	Expert Declaration of Ivan T. Hofmann in Support of Petitioners' Reply ("Hofmann Report") — Filed under seal
1163	Hofmann CV
1164	Not Used
1165	*Eyes: How They Work, Anatomy & Common Conditions*, CLEVELAND CLINIC, https://my.clevelandclinic.org/health/body/21823-eyes (last visited Jan. 21, 2024).
1166	*Nat'l Inst. Health, Ncbi Bookshelf*, THE OCULAR CIRCULATION, https://www.ncbi.nlm.nih.gov/books/NBK53329/ (last visited Jan. 5, 2024).
1167	https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=208144&Appl_type=N, accessed February 14, 2025 ("Lumify Orange Book Patent List")
1168	https://assignment.uspto.gov/patent/index.html#/patent/search/resultAbstract?id=11596600&type=patNum, accessed February 14, 2025 ("Patent Assignment for US 11,596,600")
1169	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208144Orig1s017lbl.pdf, accessed February 14, 2025 ("Lumify Label")
1170	Dr. Reddy's Laboratories Limited Form 20-F, For the Fiscal Year Ended March 31, 2024, available at https://www.drreddys.com/cms/cms/sites/default/files/2024-06/DR%20REDDYS%20LABORATORIES%20LTD_0.pdf, accessed February 14, 2025
1171	Expert Declaration of Ivan T. Hofmann in Support of Petitioner Reply in IPR2022-00142 — Filed under seal
1172	Bausch Fourth Quarter 2018 Earnings Call Transcript, dated February 20, 2019, available at https://seekingalpha.com/article/4242568-

	bausch-health-companies-inc-bhc-ceo-joseph-papa-on-q4-2018-results-earnings-call-transcript, accessed February 14, 2025
1173	Bausch Second Quarter 2019 Earnings Call Transcript, dated August 6, 2019, available at https://seekingalpha.com/article/4282236-bausch-health-companies-inc-bhc-ceo-joseph-papa-on-q2-2019-results-earnings-call-transcript, accessed February 17, 2025
1174	Bausch Fourth Quarter 2020 Earnings Call Transcript, dated February 24, 2021, available at https://seekingalpha.com/article/4408646-bausch-health-companies-inc-bhc-ceo-joe-papa-on-q4-2020-results-earnings-call-transcript, accessed February 17, 2025
1175	Bausch Fourth Quarter 2021 Earnings Call Transcript, dated February 23, 2022, available at https://seekingalpha.com/article/4489552-bausch-health-companies-inc-bhc-ceo-joseph-papa-on-q4-2021-results-earnings-call-transcript, accessed February 17, 2025
1176	Deposition Transcript of John Ferris, dated January 30, 2025—Filed under seal
1177	https://strength.barrys.com, accessed February 19, 2025 ("Barry's Find Your Strength")
1178	https://www.hg.agency/news/muse-awards, accessed February 17, 2025 ("HG 2019 Muse Creative Awards")
1179	https://www.hg.agency/, accessed February 17, 2025 ("HG Agency")
1180	https://museaward.com/, accessed February 17, 2025 ("MUSE Awards")
1181	https://museaward.com/winner-info.php?id=2187, accessed February 17, 2025 ("Muse Awards 2019 Silver Information")
1182	https://museaward.com/winner-info.php?id=2186, accessed February 17, 2025 ("Muse Awards 2019 Rose Gold Winner Information")
1183	https://wavemakerglobal.com/usa/news-wavemaker-us-wins-two-gold-effie-awards, accessed February 17, 2025 ("Wavemaker Global — Two Gold Effies")
1184	https://wavemakerglobal.com/our-work, accessed February 17, 2025 ("Wavemaker Global — Our Work")
1185	https://www.businesswire.com/news/home/20230926043168/en/Bausch-Lomb-Launches-LUMIFY-EYE-ILLUMINATIONS%E2%84%A2-in-the-United-States, accessed February 17, 2025 ("Businesswire — Lumify Eye Illuminations")
1186	https://www.lumifyeyes.com/eye-illuminations/, accessed February 17, 2025 ("LumifyEyes — Lumify Eye Illuminations")

1187	https://www.fiercepharma.com/marketing/bausch-lomb-kickstarts-tiktok-campaign-lumify-it-asks-consumers-dance-their-eyes, accessed February 17, 2025 ("FiercePharma – Bausch + Lomb kicks off TikTok Challenge for Lumify")
1188	Deposition Transcript of John Ferris, dated November 2, 2022, IPR2022-00142—Filed under seal
1189	https://www.prnewswire.com/news-releases/bausch--lomb-launches-the-lumifyeyedance-challenge-on-tiktok-301594922.html, accessed February 17, 2025 ("PR NewsWire – Bausch + Lomb Launches #LUMIFYEyeDance")
1190	https://www.tiktok.com/tag/lumifyeyedance?lang=en, accessed November 17, 2022 ("TikTok Lumify Eye Dance (November 2022)")
1191	https://www.ftc.gov/system/files/documents/plain-language/1001a-influencer-guide-508_1.pdf, accessed February 17, 2025 (FTC Disclosures 101 for Social Media Influencers")
1192	https://www.tiktok.com/@allanface/video/7129967072628657454?is_copy_url=1&is_from_webapp=v1&lang=en, accessed November 17, 2022 ("TikTok Allanface Video")
1193	https://www.tiktok.com/@orionsisters/video/7124396970558459179?is_copy_url=1&is_from_webapp=v1&lang=en, accessed November 17, 2022 ("TikTok OrionSisters Video")
1194	https://www.prnewswire.com/news-releases/bausch--lomb-lumifyeyedance-challenge-wins-2022-public-relations-and-marketing-excellence-award-for-external-campaign-of-the-year-from-business-intelligence-group-301664009.html, accessed February 17, 2025 ("Bausch + Lomb #LUMIFYEyeDance Challenge Wins 2022 Public Relations")
1195	https://www.eventmarketer.com/article/coachella-2024-experiential-marketing/, accessed February 17, 2025 (Event Marketer Coachella 2024 Experimental Marketing")
1196	Deposition Transcript of John Ferris, dated January 4, 2024, C.A. No. 21-16766—filed under seal
1197	Deposition Transcript of John C. Jarosz, dated February 12, 2025—Filed under seal
1198	Declaration of John C. Jarosz, IPR2022-00142—Filed under seal
1199	Deposition Transcript of John C. Jarosz, dated November 11, 2022. IPR2022-00142
1200	https://www.instagram.com/barrys/reel/DFfwk5ZPoJf/, accessed February 19, 2025

1201	U.S. Patent No. 9,259,425
1202 NEW	CV of Anthony M. Masztak
1203 NEW	Expert Declaration of Anthony M. Masztak in Support of Petitioners' Reply (substitute for EX-1162)—Filed under seal

Dated: April 1, 2025

Respectfully submitted,

/Linnea P. Cipriano/

Linnea P. Cipriano
(Reg. No. 67,729)
Goodwin Procter LLP
620 Eighth Avenue
New York, NY 10018
Phone: (212) 813-8800
Cell: (443) 235-1739
Fax: (212) 937-2204
lcipriano@goodwinlaw.com

Counsel for Petitioners Dr. Reddy's Laboratories S.A. and Dr. Reddy's Laboratories, Inc.

CERTIFICATE OF SERVICE

I, Linnea P. Cipriano, certify that I caused to be served a true and correct copy of the foregoing **PETITIONERS' FIFTH UPDATED EXHIBIT LIST** by email, as follows:

Bryan Diner	bryan.diner@finnegan.com
Justin Hasford	justin.hasford@finnegan.com
Joshua Goldberg	joshua.goldberg@finnegan.com
Matthew Luneack	matthew.luneack@finnegan.com
Kassandra Officer	kassandra.officer@finnegan.com
Christina Yang	christina.yang@finnegan.com
Ryan V. McDonnell	ryan.mcdonnell@finnegan.com
M. David Weingarten	david.weingarten@finnegan.com
Ryan P. O'Quinn	ryan.o'quinn@finnegan.com

April 1, 2025

/Linnea P. Cipriano/

Linnea P. Cipriano
(Reg. No. 67,729)
Goodwin Procter LLP
620 Eighth Avenue
New York, NY 10018
Phone: (212) 813-8000
Fax: (212) 937-2204
lcipriano@goodwinlaw.com

Counsel for Petitioners